Healthcare provider profile · identity verified

Krishna Vijay Persaud, MD

Allopathic & Osteopathic Physicians|Internal Medicine · WILLIAMSON, NY · NPI 1508829284

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Krishna Vijay Persaud, MD received $145.12 in general payments during 2025 across 2 reported records.

Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 83.1% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.

Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$145.12

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Boehringer Ingelheim Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$120.64	83.1%	1	2025
Medtronic, Inc.	Medtronic, Inc. exact · evidence 2025-07-22	$24.48	16.9%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$145.12	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
JARDIANCE Normalized: jardiance	Drug	Boehringer Ingelheim Pharmaceuticals, Inc.	$120.64	1	2025
Source payment records 2025-07-24 · Boehringer Ingelheim Pharmaceuticals, Inc. · $120.64 · Open Payments source
MINIMED 780G Normalized: minimed 780g	Device	Medtronic, Inc.	$24.48	1	2025
Source payment records 2025-08-07 · Medtronic, Inc. · $24.48 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
JARDIANCE jardiance	2025	Jardiance	2024	76	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583	Jardiance · 2024 Exact normalized brand match · 1 Part D row	76	24

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	488	124
Atorvastatin Calcium	Atorvastatin Calcium	441	142
Losartan Potassium	Losartan Potassium	425	122
Rosuvastatin Calcium	Rosuvastatin Calcium	288	95
Amlodipine Besylate	Amlodipine Besylate	256	78
Omeprazole	Omeprazole	239	72
Lisinopril	Lisinopril	226	60
Pantoprazole Sodium	Pantoprazole Sodium	225	76
Simvastatin	Simvastatin	217	68
Gabapentin	Gabapentin	202	53
Metoprolol Succinate	Metoprolol Succinate	167	57
Torsemide	Torsemide	162	44
Tamsulosin Hcl	Tamsulosin Hcl	160	55
Metformin Hcl	Metformin Hcl	129	36
Eliquis	Apixaban	123	28
Metformin Hcl Er	Metformin Hcl	114	35
Trazodone Hcl	Trazodone Hcl	110	31
Metoprolol Tartrate	Metoprolol Tartrate	105	32
Sertraline Hcl	Sertraline Hcl	105	29
Clopidogrel	Clopidogrel Bisulfate	100	24
Ezetimibe	Ezetimibe	100	28
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	89	18
Fluticasone Propionate	Fluticasone Propionate	89	30
Furosemide	Furosemide	88	37
Hydralazine Hcl	Hydralazine Hcl	88	16
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	85	17
Allopurinol	Allopurinol	84	30
Albuterol Sulfate Hfa	Albuterol Sulfate	82	28
Atenolol	Atenolol	81	26
Hydrochlorothiazide	Hydrochlorothiazide	77	29
Jardiance	Empagliflozin	76	24
Bupropion Xl	Bupropion Hcl	72	20
Famotidine	Famotidine	69	23
Meloxicam	Meloxicam	69	20
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	64	18
Oxycodone Hcl	Oxycodone Hcl	63	12
Pregabalin	Pregabalin	61	15
Clonazepam	Clonazepam	58	12
Ozempic	Semaglutide	57	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	52	18
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	51	11
Alprazolam	Alprazolam	50	14
Escitalopram Oxalate	Escitalopram Oxalate	50	19
Carvedilol	Carvedilol	49	14
Isosorbide Mononitrate Er	Isosorbide Mononitrate	47	12
Propranolol Hcl	Propranolol Hcl	47	12
Warfarin Sodium	Warfarin Sodium	47	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	45	21
Duloxetine Hcl	Duloxetine Hcl	44	14
Fenofibrate	Fenofibrate Nanocrystallized	44	11
Finasteride	Finasteride	44	13
Prednisone	Prednisone	44	37
Shingrix	Varicella-Zoster Ge/As01b/Pf	44	36
Tramadol Hcl	Tramadol Hcl	44	13
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	43	11
Naproxen	Naproxen	42	18
Buspirone Hcl	Buspirone Hcl	40	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	40	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	40	11
Pravastatin Sodium	Pravastatin Sodium	40	suppressed
Glimepiride	Glimepiride	39	12
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	39	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	38	12
Fenofibrate	Fenofibrate	37	suppressed
Labetalol Hcl	Labetalol Hcl	37	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	37	11
Pilocarpine Hcl	Pilocarpine Hcl	37	suppressed
Farxiga	Dapagliflozin Propanediol	34	11
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	34	suppressed
Cefdinir	Cefdinir	33	29
Citalopram Hbr	Citalopram Hydrobromide	33	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	33	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	33	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	32	13
Memantine Hcl	Memantine Hcl	32	suppressed
Oxycontin	Oxycodone Hcl	32	suppressed
Ropinirole Hcl	Ropinirole Hcl	31	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	30	suppressed
Lansoprazole	Lansoprazole	30	suppressed
Amoxicillin	Amoxicillin	29	19
Cyproheptadine Hcl	Cyproheptadine Hcl	29	suppressed
Ibuprofen	Ibuprofen	29	12
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	29	22
Ramipril	Ramipril	29	suppressed
Chlorthalidone	Chlorthalidone	28	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	28	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	28	13
Azithromycin	Azithromycin	27	suppressed
Lorazepam	Lorazepam	27	suppressed
Lovastatin	Lovastatin	26	suppressed
Breo Ellipta	Fluticasone/Vilanterol	24	suppressed
Donepezil Hcl	Donepezil Hcl	24	suppressed
Meclizine Hcl	Meclizine Hcl	24	11
Mirtazapine	Mirtazapine	24	12
Modafinil	Modafinil	24	suppressed
Risperidone	Risperidone	24	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	24	17
Amitriptyline Hcl	Amitriptyline Hcl	23	suppressed
Diclofenac Sodium	Diclofenac Sodium	23	12
Esomeprazole Magnesium	Esomeprazole Magnesium	23	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	23	suppressed
Synthroid	Levothyroxine Sodium	23	suppressed
Celecoxib	Celecoxib	22	suppressed
Ibandronate Sodium	Ibandronate Sodium	22	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	22	suppressed
Valacyclovir	Valacyclovir Hcl	22	suppressed
Verapamil Er	Verapamil Hcl	21	suppressed
Fentanyl	Fentanyl	20	suppressed
Potassium Chloride	Potassium Chloride	20	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	19	19
Clobetasol Propionate	Clobetasol Propionate	19	12
Ipratropium Bromide	Ipratropium Bromide	19	suppressed
Irbesartan	Irbesartan	19	suppressed
Montelukast Sodium	Montelukast Sodium	19	suppressed
Nifedipine Er	Nifedipine	19	suppressed
Alendronate Sodium	Alendronate Sodium	18	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Myrbetriq	Mirabegron	17	suppressed
Nitroglycerin	Nitroglycerin	17	13
Zolpidem Tartrate	Zolpidem Tartrate	17	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	16	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	16	suppressed
Dexlansoprazole Dr	Dexlansoprazole	16	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	16	12
Fluconazole	Fluconazole	16	suppressed
Humalog Kwikpen U-100	Insulin Lispro	16	suppressed
Lithium Carbonate	Lithium Carbonate	16	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	16	suppressed
Qvar Redihaler	Beclomethasone Dipropionate	16	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Trintellix	Vortioxetine Hydrobromide	16	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	15	15
Cholestyramine	Cholestyramine (With Sugar)	15	suppressed
Enalapril Maleate	Enalapril Maleate	15	suppressed
Gemtesa	Vibegron	15	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	15	suppressed
Methylprednisolone	Methylprednisolone	15	13
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Carisoprodol	Carisoprodol	14	suppressed
Entresto	Sacubitril/Valsartan	14	suppressed
Lamotrigine	Lamotrigine	14	suppressed
Linzess	Linaclotide	14	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	14	suppressed
Cephalexin	Cephalexin	13	12
Cilostazol	Cilostazol	13	suppressed
Levemir Flexpen	Insulin Detemir	13	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Trospium Chloride Er	Trospium Chloride	13	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Lubiprostone	Lubiprostone	12	suppressed
Midodrine Hcl	Midodrine Hcl	12	suppressed
Phenobarbital	Phenobarbital	12	suppressed
Rybelsus	Semaglutide	12	suppressed
Sucralfate	Sucralfate	12	suppressed
Testosterone	Testosterone	12	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	11
Glipizide Er	Glipizide	11	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Sildenafil Citrate	Sildenafil Citrate	11	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	11	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$145.12 · 2 records	Boehringer Ingelheim Pharmaceuticals, Inc.	JARDIANCE, MINIMED 780G	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Jardiance play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error